Navigation Links
GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy

of TNF(alpha), and the ability of adenovectors to selectively deliver the TNF(alpha) gene to cancer cells," stated C. Richter King, Ph.D., GenVec's Senior Vice President of Research. "These findings support the broad applicability of our core technology for use in the treatment of cancer," added Dr. King.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TNFerade(TM) is currently in a pivotal Phase II/III study (PACT) in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, and seasonal and pandemic flu. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future programs and studies, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; the timing and content of future U.S. Food and Drug Administration regulatory actions with respect to GenVec, its product cand
'"/>




Page: 1 2 3

Related medicine technology :

1. GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade at ASCO
2. GenVec Presents Research on New Ad35 Adenovector at ARVO
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/21/2014)... ARMONK , N.Y. and HAMBURG, Germany ... today announced it is collaborating with Deutsches Elektronen-Synchrotron ( ... Germany , to speed up management and ... Big Data and Analytics architecture based on ... gigabyte per second of data at peak performance and ...
(Date:8/21/2014)... 2014  ACI Clinical ( www.aciclinical.com ) announces ... Committees. Using this solution, trial sponsors ... standard costs and receive the same expertise that ... services. Leveraging a decade of DMC ... development, statistical programming and meeting facilitation), ACI analyzed ...
(Date:8/21/2014)... 21, 2014 CVS Caremark Corporation (NYSE: ... Yields and consideration payable in connection with its previously announced ... 2014 for (1) any and all of its 6.250% Senior ... up to a maximum amount of its 6.125% Senior Notes ... Notes due 2017 (collectively, the "Maximum Tender Offer Notes" and ...
Breaking Medicine Technology:DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
(Date:8/21/2014)... of Texas MD Anderson Cancer Center today announced a ... breast screening at a network of community breast care ... late November, MD Anderson will become the exclusive provider ... Hermann,s 10 breast care centers, located in Memorial City, ... time, the network will expand to Memorial Hermann,s locations ...
(Date:8/21/2014)... 21, 2014 (HealthDay News) -- Black mothers are less ... here,s one possible reason why: Hospitals in neighborhoods with ... those in areas with more white residents, a U.S. ... are much less common in medical centers where the ... U.S. Centers for Disease Control and Prevention reported Thursday. ...
(Date:8/21/2014)... By Dennis Thompson ... (HealthDay News) -- A combination of therapy and antidepressants ... depression, a new study reports. Four out of ... two years experienced full recovery when treated with cognitive ... other hand, the combination didn,t work much better than ...
(Date:8/21/2014)... Seattle, WA chiropractors Dr. Lincoln ... Chiropractic and Massage Center have recently welcomed two ... Rina Lang, LMP and Mike Larios, LMP have specialized ... techniques, and have developed their expertise working in a ... important in a clinical environment where massage is used ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The results ... today in The Journal of the American Medical Association ... invasive cancers and reduces unnecessary recalls. Memorial Healthcare System ... the study. , “This study confirms what we already ... harmful cancers we want to find and, at the ...
Breaking Medicine News(10 mins):Health News:MD Anderson and Memorial Hermann to operate breast screening network across Houston area 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 2Health News:Seattle’s Eastlake Chiropractic and Massage Center Is Pleased to Introduce Rina Lang and Mike Larios as New Members of Its Massage Therapy Team 3Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2
... The More You Know, the More You Care About ... Action for World,s Leaders,to ,Put a Face on the ... 25 years,after HIV was discovered, one-third of the people ... about the global HIV and AIDS epidemic,and one-fourth believe ...
... Peninsula Medical School in the South West of England ... providing out of hours services in primary care are ... discussions and carried out telephone interviews with 27 patients ... general practice cover in the evenings and weekends in ...
... female hormone , THURSDAY, Nov. 29 (HealthDay News) -- ... given with estrogen in hormone replacement therapy -- offers ... , They conducted tests on female mice genetically engineered ... conclusion. , Treatment with estrogen blocked the Alzheimer,s-like symptoms ...
... 29 S3 Matching Technologies,patented TeraMatch(R) has ... (TMHP) innovative technology to automate the verification ... that Medicaid does not,allow payments to non-qualified ... TMHP relied on manual data verification searches ...
... to Create New, Database File Storage System to ... Nov. 29 ONStor Inc., the leading,provider of ... that Consortium Health Plans, Inc., a national consortium ... has chosen the ONStor,Bobcat Series NAS Gateway as ...
... STAAR Surgical,Company (Nasdaq: STAA ), a ... products, today announced that it will,present at the ... on,Tuesday, December 4, 2007 at the Millennium Broadway ... Surgical,s Chief Executive Officer, will,discuss the Company,s business ...
Cached Medicine News:Health News:AIDS Ignorance: One-Third of Adults Admit Little or No Knowledge of Pandemic 2Health News:AIDS Ignorance: One-Third of Adults Admit Little or No Knowledge of Pandemic 3Health News:AIDS Ignorance: One-Third of Adults Admit Little or No Knowledge of Pandemic 4Health News:Out-of-hours doctors reluctant to do home visits, say patients 2Health News:Progesterone Won't Shield Women Against Alzheimer's 2Health News:S3 Matching Technologies Aids in Reducing Risk to Texas Medicaid System 2Health News:Consortium Health Plans Cuts Down on Power Usage and Cooling in Its Data Center Using ONStor's Green Clustered NAS Solution 2Health News:Consortium Health Plans Cuts Down on Power Usage and Cooling in Its Data Center Using ONStor's Green Clustered NAS Solution 3Health News:STAAR Surgical to Present at the BMO Capital Markets Focus on Healthcare Conference 2
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... is the same as model ... flat internal baffle across the ... baffle slopes forward, leaving space ... sweep the deck and space ...
... The Benchtop Fume Hood is an ... installations in which a number of fume ... schools, junior colleges and universities. Features include ... polyethylene with rounded inside corners for easy ...
This is the second generation of the famous A/O sliding microtome, manufactured in the United States under the Leica trademark....
Medicine Products: